Partial
Mostly Aligned
Patient Risk:
Low
Summary
Partial alignment with the prescribing information. Several claims are supported (mechanism, common adverse effects, general dose-relationship concepts), but there is at least one direct contradiction (anxiolytic dosing), and multiple important safety/dosing details are omitted.
Category Scores
Accurate Statements
The amount of hydroxyzine that is considered "too much" depends on several factors, including the patient's age, weight, medical condition, and the reason for taking the medication.
DOSAGE (supported)
Dosage recommendations are individualized to ensure both safety and efficacy.
DOSAGE (supported)
For adults, typical dosages for itching (pruritus) range from 25 mg to 100 mg, taken up to four times daily as needed.
DOSAGE (supported)
Taking too much hydroxyzine can lead to an overdose.
OVERDOSAGE (supported)
Common side effects include drowsiness, dry mouth, and blurred vision.
ADVERSE REACTIONS (partially supported); ANTICHOLINERGIC (supporting note)
Hydroxyzine is an antihistamine that works by blocking the action of histamine, a substance in the body that causes allergic symptoms.
CLINICAL PHARMACOLOGY (supported)
It also has anticholinergic and sedative effects, which contribute to its use in managing anxiety and nausea.
CLINICAL PHARMACOLOGY (supported)
Unsupported Statements
For anxiety, the usual starting dose for adults is 25 mg to 100 mg taken four times daily.
Label indicates anxiolytic dosing as 50–100 mg q.i.d. in adults; the claimed 25–100 mg q.i.d. starting range is not supported by the provided label text.
Doses for children are calculated based on their weight, typically ranging from 0.5 to 1 mg per kilogram of body weight per dose, not to exceed 10 mg per kilogram of body weight per day.
The pediatric dosing details are not clearly stated in the provided dosage text with those exact weight-based per-dose and daily maximum figures.
Symptoms of an overdose can include pronounced drowsiness, nausea, vomiting, involuntary muscle movements, confusion, hallucinations, and, in severe cases, heart rhythm abnormalities or seizures.
The overdosage section lists hypersedation and references other management details; the exact symptom set may not be enumerated as stated.
Immediate medical attention is crucial if an overdose is suspected.
Overdosage management guidance is provided, but the specific directive to seek immediate care is not explicitly stated in the excerpt.
The primary risks associated with hydroxyzine are related to its side effects, which can be more pronounced at higher doses.
Dose-related risk statements are not explicitly tied to higher-dose risk in the provided sections beyond general warning language.
More serious risks include a potentially fatal heart rhythm problem called QT prolongation, especially when combined with other medications that affect the heart rhythm or in individuals with pre-existing heart conditions.
QT prolongation is not described as a boxed warning or explicit cardiotoxic risk in the provided label excerpts.
Drowsiness can impair the ability to drive or operate machinery.
A driving impairment statement is not explicitly present in the provided label excerpts.
Contradictions
Low
AI Statement
For anxiety, the usual starting dose for adults is 25 mg to 100 mg taken four times daily.
Label Reference
DOSAGE
Important Omissions
Pediatric dosing details by weight with explicit per-dose and daily maximums are not clearly provided in the excerpt; the exact weight-based ranges requested are not confirmed.
Importance:
Moderate
Overdose symptom specifics beyond hypersedation (e.g., arrhythmias, seizures) are not comprehensively enumerated in the provided label excerpt.
Importance:
High
Immediate medical attention guidance for overdose is not explicitly stated in the excerpt.
Importance:
High
Explicit QT prolongation risk language and its clinical context are not present in the provided sections.
Importance:
High
Explicit driving impairment warning is not present in the provided label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Overall, the claims align with known, general safety considerations (drowsiness as a common adverse effect; overdose risk exists). However, key safety omissions (overdose symptom specifics, urgent care guidance, and cardiac risk language) reduce completeness.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement